What is Bone Biologics Corp's earnings per share (EPS)?

Bone Biologics Corp (BBLG) reported diluted earnings per share of -$2.65 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bone Biologics Corp Financials

BBLG

FY2025 annual

Revenue Not reported for FY2025

Net Income -$3.1M +24.4% YoY

EPS (Diluted) -$2.65 YoY not available

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

This page shows Bone Biologics Corp (BBLG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BBLG FY2025 2026-05-14

Bone Biologics is operating as a cash-funded development company, with equity financing repeatedly covering losses while R&D intensity resets lower.

The clearest shift is that cash burn eased from -$9.56M in FY2023 to -$2.69M in FY2025, but that improvement came mainly from R&D falling from $6.91M to $1.06M while SG&A stayed near $2.1M-$2.5M. That points less to operating leverage and more to management dialing development activity up or down to preserve cash between raises.

FY2025 ended with $5.33M of cash against just $419K of liabilities and no long-term debt shown, so near-term balance-sheet pressure is low even though operations remain loss-making. The current ratio of 13.8x suggests the asset base is still mostly liquidity rather than productive operating assets.

Across FY2023-FY2025, financing inflows totaled about $14.2M while operating cash outflow totaled about -$16.4M, showing outside capital has been the company’s main funding source. The retained deficit of -$88.1M means losses are cumulative, so the business has been sustained by repeated recapitalization rather than by cash generated from commercial activity.

Financial Health Signals

Financial health score not available

Bone Biologics Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Bone Biologics Corp passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Bone Biologics Corp reported a net loss of $3.1M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$3.1M

YoY+24.4%

Bone Biologics Corp reported -$3.1M in net income in fiscal year 2025. This represents an increase of 24.4% from the prior year.

EPS (Diluted)

-$2.65

Bone Biologics Corp earned -$2.65 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$5.3M

YoY+60.4%

Bone Biologics Corp held $5.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Bone Biologics Corp had 2M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-57.8%

YoY+60.2pp

Bone Biologics Corp's ROE was -57.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 60.2 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$1.1M

YoY-50.2%

5Y CAGR+25.5%

Bone Biologics Corp invested $1.1M in research and development in fiscal year 2025. This represents a decrease of 50.2% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

BBLG Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BBLG annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$1.1B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.1M-50.2%	$2.1M-69.2%	$6.9M+337.4%	$1.6M+1824.9%	$82K-75.9%	$341K	N/A	$104K-92.6%	$1.4M	N/A	$3.7M+488.0%	$624K+231.2%	$188K	N/A	N/A
SG&A Expenses	N/A	$2.2M+4.1%	$2.1M-17.1%	$2.5M+20.8%	$2.1M+104.3%	$1.0M+110.8%	$484K	N/A	$2.7M-32.1%	$4.0M	N/A	N/A	$1.5M	N/A	N/A	N/A
Operating Income	N/A	-$3.2M+23.3%	-$4.2M+55.3%	-$9.4M-157.2%	-$3.7M-232.3%	-$1.1M-33.7%	-$825K	N/A	-$2.8M-6.3%	-$2.6M	N/A	N/A	-$3.0M	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	$2K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$106K-92.5%	$1.4M+242.6%	$409K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$2K0.0%	$2K-0.2%	$2K-7.3%	$2K+8.1%	$2K-28.7%	$2K-74.6%	$9K+452.5%	$2K+100.0%	$800	N/A	N/A
Net Income	N/A	-$3.1M+24.4%	-$4.1M+54.0%	-$8.9M-502.8%	-$1.5M+7.8%	-$1.6M+11.7%	-$1.8M	N/A	-$4.4M	N/A	N/A	N/A	-$4.4M	N/A	N/A	-$938K
EPS (Diluted)	—	-$2.65	-$28.96	-$34.01	-$31.15	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$309K+118.0%	$142K	N/A	$188K-2.0%	$192K-54.8%	$424K	N/A	$430K
SG&A Expenses	$499K-24.7%	$663K	N/A	$527K-5.2%	$556K-9.5%	$615K	N/A	$521K
Operating Income	-$808K-0.4%	-$805K	N/A	-$715K+4.4%	-$748K+28.0%	-$1.0M	N/A	-$951K
Net Income	-$774K-1.0%	-$766K	N/A	-$667K+10.0%	-$741K+27.2%	-$1.0M	N/A	-$941K
EPS (Diluted)	-$0.430.0%	-$0.43	N/A	-$0.37	-$1.33	-$1.92	N/A	-$14.21

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

BBLG Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BBLG annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$5.8M+50.1%	$3.9M+3.3%	$3.7M-56.0%	$8.5M+27.3%	$6.7M	$0-100.0%	$31K-97.0%	$1.0M+30.8%	$796K+13.5%	$701K-54.7%	$1.5M-59.5%	$3.8M+4277.1%	$87K+18475.5%	$470+100.0%	-$3.9M
Current Assets	$5.8M+50.1%	$3.9M+3.3%	$3.7M-56.0%	$8.5M	N/A	N/A	$31K-97.0%	$1.0M+30.8%	$796K+13.5%	$701K-54.5%	$1.5M-59.6%	$3.8M+4263.7%	$87K	N/A	N/A
Cash & Equivalents	$5.3M+60.4%	$3.3M+9.9%	$3.0M-59.9%	$7.5M+12.9%	$6.7M	N/A	$24K-97.5%	$955K+38.4%	$690K+11.3%	$620K-44.4%	$1.1M-58.1%	$2.7M+172942.7%	$2K	N/A	N/A
Total Liabilities	$419K+10.8%	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M+15.1%	$11.9M+23.4%	$9.6M+4.9%	$9.2M+1.4%	$9.1M+57.8%	$5.7M-23.6%	$7.5M+32.0%	$5.7M+21.8%	$4.7M+15322.6%	$30K
Current Liabilities	$419K+10.8%	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M+2267.1%	$578K-94.0%	$9.6M+902.2%	$962K-36.0%	$1.5M-30.0%	$2.1M-44.6%	$3.9M-32.0%	$5.7M	N/A	N/A
Total Equity	$5.4M+54.4%	$3.5M+19.9%	$2.9M-51.1%	$5.9M-9.6%	$6.6M+148.0%	-$13.7M-15.4%	-$11.9M-38.0%	-$8.6M-2.4%	-$8.4M-0.4%	-$8.4M-99.2%	-$4.2M-13.5%	-$3.7M+34.1%	-$5.6M-19.9%	-$4.7M-18.1%	-$4.0M
Retained Earnings	-$88.1M-3.7%	-$85.0M-5.1%	-$80.9M-12.4%	-$72.0M-2.1%	-$70.5M-2.3%	-$68.9M-2.7%	-$67.0M-5.4%	-$63.6M-7.5%	-$59.2M-13.5%	-$52.1M-101.2%	-$25.9M-115.3%	-$12.0M-58.1%	-$7.6M-12536.9%	$61K+210.7%	-$55K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$4.4M-10.9%	$5.0M-14.1%	$5.8M-8.7%	$6.4M-9.3%	$7.0M+121.4%	$3.2M-18.1%	$3.9M-5.0%	$4.1M
Current Assets	$4.4M-10.9%	$5.0M-14.1%	$5.8M-8.7%	$6.4M-9.3%	$7.0M+121.4%	$3.2M-18.1%	$3.9M-5.0%	$4.1M
Cash & Equivalents	$4.0M-11.0%	$4.5M-15.1%	$5.3M-11.8%	$6.0M-8.9%	$6.6M+141.8%	$2.7M-17.4%	$3.3M-6.8%	$3.6M
Total Liabilities	$512K+65.5%	$309K-26.1%	$419K+25.2%	$334K-17.7%	$406K+61.7%	$251K-33.5%	$378K+38.2%	$273K
Current Liabilities	$512K+65.5%	$309K-26.1%	$419K+25.2%	$334K-17.7%	$406K+61.7%	$251K-33.5%	$378K+38.2%	$273K
Total Equity	$3.9M-16.0%	$4.7M-13.2%	$5.4M-10.6%	$6.0M-8.8%	$6.6M+126.6%	$2.9M-16.4%	$3.5M-8.1%	$3.8M
Retained Earnings	-$89.7M-0.9%	-$88.9M-0.9%	-$88.1M-0.8%	-$87.4M-0.8%	-$86.8M-0.9%	-$86.0M-1.2%	-$85.0M-1.8%	-$83.5M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BBLG Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BBLG annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$2.6M	-$2.7M+34.8%	-$4.1M+56.8%	-$9.6M-167.9%	-$3.6M-190.3%	-$1.2M-187.8%	-$427K	N/A	-$4.1M-23.3%	-$3.3M	N/A	-$3.5M-28.7%	-$2.8M	N/A	N/A	-$4K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$504-95.8%	$12K	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$3.5M-28.1%	-$2.8M	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$504-102.0%	$25K	N/A	N/A	N/A
Financing Cash Flow	N/A	$4.7M+6.3%	$4.4M-12.3%	$5.0M+13.9%	$4.4M-44.0%	$7.9M+1862.3%	$403K	N/A	$4.4M+28.5%	$3.4M	N/A	$2.0M-62.9%	$5.4M	N/A	N/A	$4K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$518K+35.5%	-$804K-12.5%	-$715K-20.9%	-$591K-28.9%	-$459K+50.5%	-$926K+31.6%	-$1.4M-136.6%	-$572K
Financing Cash Flow	N/A	N/A	$0	$0-100.0%	$4.4M+1152.4%	$348K-68.8%	$1.1M-38.4%	$1.8M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BBLG Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BBLG annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Margin	N/A	N/A	N/A	N/A	N/A	-0.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-0.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-57.8%+60.2pp	-118.1%+189.8pp	-307.9%-282.9pp	-25.0%-0.5pp	-24.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-53.6%+52.9pp	-106.5%+132.9pp	-239.4%-221.9pp	-17.5%+6.6pp	-24.1%	N/A	N/A	-425.7%	N/A	N/A	N/A	-115.8%	N/A	N/A	23.9%
Current Ratio	13.85+3.6x	10.22+5.7x	4.50+1.2x	3.33	N/A	N/A	0.05-0.1x	0.11-0.7x	0.83+0.4x	0.47-0.3x	0.72-0.3x	0.98+1.0x	0.02	N/A	N/A
Debt-to-Equity	0.080.0x	0.11-0.2x	0.29-0.1x	0.43+0.4x	0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-19.7%-3.3pp	-16.4%	N/A	-11.1%+0.2pp	-11.2%+23.7pp	-34.9%	N/A	-24.8%
Return on Assets	-17.4%-2.1pp	-15.4%	N/A	-10.5%+0.1pp	-10.6%+21.6pp	-32.2%	N/A	-23.1%
Current Ratio	8.67-7.4x	16.09+2.2x	13.85-5.2x	19.00+1.8x	17.24+4.7x	12.59+2.4x	10.22-4.6x	14.87
Debt-to-Equity	0.13+0.1x	0.070.0x	0.080.0x	0.060.0x	0.060.0x	0.090.0x	0.110.0x	0.07

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Similar Companies

Nuwellis Inc NUWE

$3.7M

Catheter Precision VTAK

$770K

Venus Concept Inc VERO

$2.1M

Nanovibronix Inc NAOV

$4.4M

Tivic Health Systems Inc TIVC

$4.0M

Where Bone Biologics Corp Ranks

Frequently Asked Questions

Is Bone Biologics Corp profitable?

No, Bone Biologics Corp (BBLG) reported a net income of -$3.1M in fiscal year 2025.

What is Bone Biologics Corp's return on equity (ROE)?

Bone Biologics Corp (BBLG) has a return on equity of -57.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bone Biologics Corp's operating cash flow?

Bone Biologics Corp (BBLG) recorded an outflow of $2.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Bone Biologics Corp's total assets?

Bone Biologics Corp (BBLG) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Bone Biologics Corp spend on research and development?

Bone Biologics Corp (BBLG) invested $1.1M in research and development during fiscal year 2025.

How many shares does Bone Biologics Corp have outstanding?

Bone Biologics Corp (BBLG) had 2M shares outstanding as of fiscal year 2025.

What is Bone Biologics Corp's current ratio?

Bone Biologics Corp (BBLG) had a current ratio of 13.85 as of fiscal year 2025, which is generally considered healthy.

What is Bone Biologics Corp's debt-to-equity ratio?

Bone Biologics Corp (BBLG) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bone Biologics Corp's return on assets (ROA)?

Bone Biologics Corp (BBLG) had a return on assets of -53.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bone Biologics Corp's cash runway?

Based on fiscal year 2025 data, Bone Biologics Corp (BBLG) had $5.3M in cash against an annual operating cash burn of $2.7M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bone Biologics Corp's Piotroski F-Score?

Bone Biologics Corp (BBLG) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bone Biologics Corp's earnings high quality?

Bone Biologics Corp (BBLG) reported a net loss of $3.1M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.